Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

52.39 +4.29 (+8.92%)
Streaming Delayed Price Updated: 10:49 AM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
News headline image
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity ↗
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its... 
Via Benzinga
News headline image
Why Novo Nordisk Stock Popped After Earnings ↗
Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs. 
Via The Motley Fool
News headline image
Novo Nordisk Predicts Strong Second Half ↗
Via The Motley Fool
News headline image
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated ↗
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook ↗
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition. 
Via Benzinga
Topics Earnings
News headline image
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump. ↗
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 view. 
Via Investor's Business Daily
News headline image
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth ↗
Hims & Hers is on fire right now. 
Via The Motley Fool
News headline image
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed ↗
Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments. 
Via Benzinga
News headline image
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected ↗
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now... 
Via Benzinga
Topics Bankruptcy
News headline image
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped ↗
Good news for Hims & Hers stock spooks Lilly and Novo investors. 
Via The Motley Fool
Topics Earnings
News headline image
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant? 
Via MarketBeat
Topics Earnings
News headline image
Novo Nordisk's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
Top 1% Stock, Hims & Hers Health, Dives On Lackluster Outlook ↗
The company recently inked a deal with Novo Nordisk. But will that bolster current-quarter sales? 
Via Investor's Business Daily
News headline image
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April ↗
Via The Motley Fool
News headline image
Hims & Hers Names New COO. Stock Rallies. ↗
Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery ↗
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas. 
Via Benzinga
News headline image
3 No-Brainer Stocks to Buy in May ↗
Via The Motley Fool
News headline image
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
News headline image
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data ↗
Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution. 
Via Benzinga
News headline image
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say ↗
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential. 
Via Benzinga
News headline image
Why Is Novo Nordisk Stock Trading Higher On Friday? ↗
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity. 
Via Benzinga
News headline image
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday ↗
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
News headline image
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024. 
Via MarketBeat
Topics Regulatory Compliance
News headline image
Is Novo Nordisk Stock a Buy? ↗
Via The Motley Fool
News headline image
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment ↗
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives. 
Via Benzinga
News headline image
CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance ↗
CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare performance. 
Via Benzinga
News headline image
Why Novo Nordisk Stock Popped Today ↗
Guess WHO thinks Novo Nordisk stock is a buy now? 
Via The Motley Fool
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Affordable Growth Candidate ↗
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Affordable Growth Candidate 
Via Chartmill
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.